Researchers are developing medications that target multiple hormones involved in hunger, blood sugar, and energy balance
Community protocols describe 250-500 mcg subcutaneous daily, near-umbilical for GI-targeted effect, over 4-6 weeks during dose escalation
It has been studied for its potential to promote tissue repair, reduce inflammation, and support overall recovery
15 Phase II trials targeting MASH have shown that treatment with SEMA 0.4 mg daily for 72 weeks resulted in more patients with liver fibrosis stage F2/F3 achieving improvement in MASH without progression of liver fibrosis (odds ratio = 6.87, 95% CI = 2.6017.63) compared to placebo
B12 supplementation is particularly important because reduced food intake naturally reduces B12 consumption, and B12 deficiency causes fatigue that further reduces physical activity